Collegium Pharmaceutical Sees Exceptional Financial Growth in Q3
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has reported impressive financial results for the third quarter, highlighting a record net revenue of $209.4 million, which marks a remarkable 31% increase from the previous year. This surge demonstrates the company’s ability to innovate and deliver products that resonate well with the market.
Key Revenue Drivers in Third Quarter
During this quarter, the company generated a record $41.8 million from its Jornay PM segment, which reflects a 20% growth in prescriptions. With the approaching back-to-school season, both patients and healthcare providers have increasingly recognized the unique benefits of Jornay PM for managing ADHD. Furthermore, Collegium's pain portfolio net revenue reached $167.6 million, up by 11% year-over-year, with consistent year-over-year growth across all three core products.
Financial Performance Highlights
Vikram Karnani, President and CEO of Collegium, expressed his enthusiasm over the results, attributing the strong quarter to their portfolio of differentiated medicines and their commitment to patient care. Financial performance was strong across the board, with an adjusted EBITDA increase of 27% year-over-year, reaching $133 million. The strong performance allowed the company to revise its full-year 2025 net revenue guidance upward to between $775 and $785 million, along with an adjusted EBITDA guidance of $460 to $470 million.
Growth in ADHD and Pain Management Sectors
Looking specifically at the ADHD segment, the growth of Jornay PM has been particularly notable. The company has reached an all-time high in the number of prescribers, with 27,700 healthcare providers now recommending Jornay PM. This indicates a broadening acceptance of the medication within the healthcare community. It’s anticipated that full-year Jornay PM revenues will align with the updated guidance of between $145 million and $150 million.
Pain Portfolio Performance
In the pain management sector, the company achieved a record $167.6 million in net revenue. Belbuca revenue grew by 10% to $58.3 million, while Xtampza ER saw a modest growth of 2%, generating $50.5 million. Likewise, the Nucynta franchise brought in $54.8 million, reflecting a substantial increase of 21% from the previous year. This growth indicates a robust demand for Collegium's offerings in pain management.
Strategic Initiatives and Future Outlook
Collegium has recently focused on several strategic initiatives, including a new share repurchase program approved by the Board of Directors, which allows for up to $150 million in stock buybacks through the end of 2026. In the recent months, management also celebrated the company’s 10-year anniversary on the Nasdaq, marking a decade of innovation and growth in the biopharmaceutical sector.
Upcoming Investor Conferences
Collegium Pharmaceutical will be active in the investment landscape, with participation scheduled in several upcoming investor conferences. Notably, the company will appear at the Jefferies London Healthcare Conference on November 19, the Piper Sandler 37th Annual Healthcare Conference on December 2, and the Evercore 8th Annual Healthcare Conference on December 4. These events serve as significant opportunities for engaging with investors and showcasing Collegium's impressive advancements.
Frequently Asked Questions
What were the key financial results for Q3 2025?
Collegium reported a record net revenue of $209.4 million for Q3 2025, an increase of 31% compared to the previous year.
How has the prescription growth for Jornay PM impacted revenues?
Jornay PM generated $41.8 million in net revenue, with a significant 20% increase in prescriptions during Q3.
What is the updated guidance for Collegium's 2025 revenues?
The company has raised its full-year 2025 net revenue guidance to between $775 and $785 million.
What are the highlights of Collegium's pain management portfolio?
Collegium achieved record net revenues of $167.6 million in its pain portfolio for Q3, with all three core products showing year-over-year growth.
What strategic steps has Collegium taken recently?
The Board approved a share repurchase program worth up to $150 million and has plans for active participation in several key investor conferences.
